The Fragile X Protein binds mRNAs involved in cancer progression and modulates metastasis formation

The role of the fragile X mental retardation protein (FMRP) is well established in brain, where its absence leads to the fragile X syndrome (FXS). FMRP is almost ubiquitously expressed, suggesting that, in addition to its effects in brain, it may have fundamental roles in other organs. There is evidence that FMRP expression can be linked to cancer. FMR1 mRNA, encoding FMRP, is overexpressed in hepatocellular carcinoma cells. A decreased risk of cancer has been reported in patients with FXS while a patient‐case with FXS showed an unusual decrease of tumour brain invasiveness. However, a role for FMRP in regulating cancer biology, if any, remains unknown. We show here that FMRP and FMR1 mRNA levels correlate with prognostic indicators of aggressive breast cancer, lung metastases probability and triple negative breast cancer (TNBC). We establish that FMRP overexpression in murine breast primary tumours enhances lung metastasis while its reduction has the opposite effect regulating cell spreading and invasion. FMRP binds mRNAs involved in epithelial mesenchymal transition (EMT) and invasion including E‐cadherin and Vimentin mRNAs, hallmarks of EMT and cancer progression.

[1]  B. Oostra,et al.  The Fragile X Syndrome Protein FMRP Associates with BC1 RNA and Regulates the Translation of Specific mRNAs at Synapses , 2003, Cell.

[2]  K Vajda,et al.  [Prognostic factors in breast cancer]. , 1998, Orvosi hetilap.

[3]  A. Aguilar-Lemarroy,et al.  Gene expression profiling identifies WNT7A as a possible candidate gene for decreased cancer risk in fragile X syndrome patients. , 2010, Archives of medical research.

[4]  C. Stumpf,et al.  The cancerous translation apparatus. , 2011, Current opinion in genetics & development.

[5]  C. Bagni,et al.  Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. , 2012, The Journal of clinical investigation.

[6]  S. Warren,et al.  Fragile X Syndrome: Loss of Local mRNA Regulation Alters Synaptic Development and Function , 2008, Neuron.

[7]  V. Van Belle,et al.  Lymph node ratio better predicts disease-free survival in node-positive breast cancer than the number of positive lymph nodes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Gelber,et al.  Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Licatalosi,et al.  FMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and Autism , 2011, Cell.

[10]  J. Fawcett,et al.  N-Cadherin Inhibits Schwann Cell Migration on Astrocytes , 1999, Molecular and Cellular Neuroscience.

[11]  J. Mowrey,et al.  Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. , 2009, American journal of human genetics.

[12]  Michelle N. Ngo,et al.  Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model , 2008, Journal of Medical Genetics.

[13]  J. Turk.  Fragile X syndrome: lifespan developmental implications for those without as well as with intellectual disability , 2011, Current opinion in psychiatry.

[14]  A. Satelli,et al.  Vimentin in cancer and its potential as a molecular target for cancer therapy , 2011, Cellular and Molecular Life Sciences.

[15]  C. Bagni,et al.  Fragile X mental retardation protein control of neuronal mRNA metabolism: Insights into mRNA stability , 2010, Molecular and Cellular Neuroscience.

[16]  S. Formenti,et al.  Translational control in cancer , 2010, Nature Reviews Cancer.

[17]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.

[18]  G. Sauter,et al.  Changes in Cytoskeletal Protein Composition Indicative of an Epithelial-Mesenchymal Transition in Human Micrometastatic and Primary Breast Carcinoma Cells , 2005, Clinical Cancer Research.

[19]  P. Lollini,et al.  TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma , 1983, Clinical & Experimental Metastasis.

[20]  P. V. van Diest,et al.  The origin of vimentin expression in invasive breast cancer: epithelial–mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? , 2005, The Journal of pathology.

[21]  Simone Brabletz,et al.  E-cadherin, β-catenin, and ZEB1 in malignant progression of cancer , 2009, Cancer and Metastasis Reviews.

[22]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[23]  J. Pelletier,et al.  Tumor progression and metastasis: role of translational deregulation. , 2012, Anticancer research.

[24]  Renzo Boldorini,et al.  Frequent alterations in the expression of serine/threonine kinases in human cancers. , 2006, Cancer research.

[25]  S. Ye,et al.  Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray , 2002, Journal of Cancer Research and Clinical Oncology.

[26]  Joseph,et al.  Imagable 4T1 model for the study of late stage breast cancer , 2008, BMC Cancer.

[27]  J. Darnell,et al.  Microarray Identification of FMRP-Associated Brain mRNAs and Altered mRNA Translational Profiles in Fragile X Syndrome , 2001, Cell.

[28]  Bassem A. Hassan,et al.  Decreased expression of the GABAA receptor in fragile X syndrome , 2006, Brain Research.

[29]  Zhenqing Feng,et al.  Identification of differential expression of genes in hepatocellular carcinoma by suppression subtractive hybridization combined cDNA microarray. , 2007, Oncology reports.

[30]  Elaine Fuchs,et al.  Cyfip1 Is a Putative Invasion Suppressor in Epithelial Cancers , 2009, Cell.

[31]  E. Schuman,et al.  Calcium-dependent dynamics of cadherin interactions at cell–cell junctions , 2011, Proceedings of the National Academy of Sciences.

[32]  I. Weiler,et al.  RNA Cargoes Associating with FMRP Reveal Deficits in Cellular Functioning in Fmr1 Null Mice , 2003, Neuron.

[33]  Erik Sahai,et al.  The actin cytoskeleton in cancer cell motility , 2009, Clinical & Experimental Metastasis.

[34]  J. Massagué,et al.  Epithelial-Mesenchymal Transitions Twist in Development and Metastasis , 2004, Cell.

[35]  G. Berx,et al.  Involvement of members of the cadherin superfamily in cancer. , 2009, Cold Spring Harbor perspectives in biology.

[36]  M. Nieto,et al.  The epithelial-mesenchymal transition under control: global programs to regulate epithelial plasticity. , 2012, Seminars in cancer biology.

[37]  Erik Sahai,et al.  Illuminating the metastatic process , 2007, Nature Reviews Cancer.

[38]  Francisco Portillo,et al.  The transcription factor Snail controls epithelial–mesenchymal transitions by repressing E-cadherin expression , 2000, Nature Cell Biology.

[39]  J. Held-Feindt,et al.  Spheroid confrontation assay: a simple method to monitor the three-dimensional migration of different cell types in vitro. , 2011, Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft.

[40]  R. Lothe,et al.  MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines , 2011, BMC Cancer.

[41]  S. Edge,et al.  Prognostic factors in breast cancer , 2005 .

[42]  R. Del Maestro,et al.  Spheroid Preparation from Hanging Drops: Characterization of a Model of Brain Tumor Invasion , 2004, Journal of Neuro-Oncology.

[43]  Raghu Kalluri,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[44]  K. Reddy,et al.  Triple-negative breast cancers: an updated review on treatment options. , 2011, Current oncology.

[45]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[46]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[47]  S. Pinder,et al.  E‐cadherin expression in invasive non‐lobular carcinoma of the breast and its prognostic significance , 2005, Histopathology.

[48]  Bernard Rachet,et al.  Cancer survival in five continents: a worldwide population-based study (CONCORD). , 2008, The Lancet. Oncology.

[49]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[50]  S. Grant,et al.  A new function for the fragile X mental retardation protein in regulation of PSD-95 mRNA stability , 2007, Nature Neuroscience.

[51]  Nicholas T. Ingolia,et al.  The translational landscape of mTOR signalling steers cancer initiation and metastasis , 2012, Nature.

[52]  M. Nieto,et al.  The ins and outs of the epithelial to mesenchymal transition in health and disease. , 2011, Annual review of cell and developmental biology.

[53]  Gerhard Christofori,et al.  EMT, the cytoskeleton, and cancer cell invasion , 2009, Cancer and Metastasis Reviews.

[54]  H. Moch,et al.  Down regulation of E-Cadherin (ECAD) - a predictor for occult metastatic disease in sentinel node biopsy of early squamous cell carcinomas of the oral cavity and oropharynx , 2011, BMC Cancer.

[55]  W. Greenough,et al.  From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome , 2005, Nature Reviews Neuroscience.

[56]  P. Maness,et al.  L1 and NCAM adhesion molecules as signaling coreceptors in neuronal migration and process outgrowth , 2008, Current Opinion in Neurobiology.

[57]  C. Hudis,et al.  Triple-negative breast cancer: an unmet medical need. , 2011, The oncologist.

[58]  Stefano Cannata,et al.  The fragile X mental retardation protein–RNP granules show an mGluR-dependent localization in the post-synaptic spines , 2007, Molecular and Cellular Neuroscience.

[59]  T. Rowlands,et al.  Cadherins and catenins in breast cancer. , 2005, Current opinion in cell biology.

[60]  E. Thiel,et al.  Quantitative real‐time RT‐PCR for detection of disseminated tumor cells in peripheral blood of patients with colorectal cancer using different mRNA markers , 2004, International journal of cancer.

[61]  Jungsuk An,et al.  Epithelial–mesenchymal transition in breast cancer correlates with high histological grade and triple‐negative phenotype , 2012, Histopathology.

[62]  B. Son,et al.  E-cadherin as a predictive marker of brain metastasis in non-small-cell lung cancer, and its regulation by pioglitazone in a preclinical model , 2012, Journal of Neuro-Oncology.

[63]  G. Pelosi,et al.  Alterations of ubiquitin ligases in human cancer and their association with the natural history of the tumor , 2009, Oncogene.

[64]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[65]  S. Zimmer,et al.  Translational control and metastatic progression: Enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs , 2004, Clinical & Experimental Metastasis.

[66]  H. Ishwaran,et al.  Lung metastasis genes couple breast tumor size and metastatic spread , 2007, Proceedings of the National Academy of Sciences.

[67]  J. Bergh,et al.  Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series , 2007, Clinical Cancer Research.

[68]  S. Agelaki,et al.  Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients , 2011, Breast Cancer Research.

[69]  S. Huffel,et al.  Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors , 2009, Breast Cancer Research and Treatment.

[70]  J. Olsen,et al.  Evidence of decreased risk of cancer in individuals with fragile X. , 2001, American journal of medical genetics.

[71]  L. Belghiti,et al.  Prognostic factors in breast cancer , 2002 .

[72]  C. Der,et al.  Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility , 2009, Cancer and Metastasis Reviews.

[73]  Mark F Bear,et al.  The pathophysiology of fragile X (and what it teaches us about synapses). , 2012, Annual review of neuroscience.

[74]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[75]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[76]  Uwe Ohler,et al.  FMR1 targets distinct mRNA sequence elements to regulate protein expression , 2012, Nature.

[77]  J. Segall,et al.  High-resolution multiphoton imaging of tumors in vivo. , 2011, Cold Spring Harbor protocols.

[78]  N. Sonenberg,et al.  The Fragile X Syndrome Protein Represses Activity-Dependent Translation through CYFIP1, a New 4E-BP , 2008, Cell.

[79]  R. Weinberg,et al.  A Perspective on Cancer Cell Metastasis , 2011, Science.

[80]  E. Berry-Kravis,et al.  Therapeutic Strategies in Fragile X Syndrome: Dysregulated mGluR Signaling and Beyond , 2012, Neuropsychopharmacology.